Encoded Therapeutics, a well-funded CNS gene therapy maker, lays off 10% of staff 

Already two years behind initial projections for a Phase I of its lead gene therapy, well-funded Encoded Therapeutics is conserving cash to stay afloat into 2026, business chief David McNinch confirmed in an email to Endpoints News.

David McNinch

The South San Francisco-based biotech,…